SCHEMBL20554635

SCHEMBL20554635

N#Cc1ccc(Oc2ccc(Cl)cc2)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 4/20 0.50
AR P10275 1/20 0.48
TTR P02766 3/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
SLC6A3 Q01959 2/20 0.45
NR1I2 O75469 1/20 0.45
LMNA P02545 1/20 0.45
PGR P06401 1/20 0.45
HSP90AA1 P07900 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
HSPA5 P11021 1/20 0.45
CBR1 P16152 1/20 0.45
SLC6A2 P23975 1/20 0.45
AGTR1 P30556 1/20 0.45
KCNH2 Q12809 4/20 0.44
SLC6A4 P31645 3/20 0.44
HTR2A P28223 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7486665 0.83 TTR (0.56) ARTTR
SCHEMBL3365482 0.83 TTR (0.70) TBXA2RARTTRMAPTHPGD
SCHEMBL14861480 0.81 TTR (0.54) TBXA2RARTTRMAPTHPGD
Soneclosan SCHEMBL29359126 0.81 TTR (0.66) TBXA2RTTRMAPTHPGDSLC6A3
Soneclosan SCHEMBL465591 0.81 TTR (0.66) TBXA2RTTRMAPTHPGDSLC6A3
SCHEMBL14861112 0.81 TTR (0.53) TBXA2RTTRMAPTHPGDSLC6A3
SCHEMBL16319500 0.81 AR (0.48) TBXA2RARMAPTHPGDSLC6A3
SCHEMBL366867 0.81 FFAR1 (0.50) TBXA2RARMAPTHPGDSLC6A3
SCHEMBL29255047 0.81 AR (0.48) TBXA2RARMAPTHPGDSLC6A3
SCHEMBL20554608 0.79 AR (0.75) TBXA2RARMAPTHPGDSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110770211-B Alpha, beta unsaturated amide compound 协和麒麟株式会社 2023-09-19 CN disclosed
CN-108430972-B Alpha, beta-unsaturated amide compound 协和麒麟株式会社 2022-12-27 CN disclosed
US-11447471-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-09-20 US disclosed
US-11332455-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-05-17 US disclosed
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-12-09 US disclosed
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-05-27 US disclosed
US-10787428-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2020-09-29 US disclosed
EP-3712129-A1 ALPHA, BETA-UNSATURATED AMIDE COMPOUND Kyowa Kirin Co., Ltd. (JP) 2020-09-23 EP disclosed
CN-110770211-A α unsaturated amide compound 协和麒麟株式会社 2020-02-07 CN disclosed
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-01-10 US disclosed
EP-3401309-A1 a, ß UNSATURATED AMIDE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2018-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, RXRA TBXA2R 371/4885AR 131/4885TTR 4326/4885
US-11447471-B2 α,β-unsaturated amide compound NR1H2, RXRA, RXRB TBXA2R 374/4885AR 113/4885TTR 4502/4885
US-10787428-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 TBXA2R 500/4885AR 60/4885TTR 4714/4885
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 TBXA2R 484/4885AR 76/4885TTR 4557/4885
US-11332455-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 TBXA2R 500/4885AR 60/4885TTR 4714/4885
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 TBXA2R 484/4885AR 76/4885TTR 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.